Loading page…
Kolon TissueGene Inc Sustainability Reports
Kolon TissueGene, Inc. is a biopharmaceutical company specializing in the development of advanced cell and gene therapies targeting orthopedic and degenerative joint disorders. Its flagship product candidate, TG-C, is a first-in-class cell and gene therapy designed for the treatment of knee osteoarthritis.
Sector: Manufacturing
Country: United States
Exchange: Korea Exchange (KOSDAQ)
LEI: 5493000SYYLC88FUL781
FIGI: BBG00HNRMTQ1
2 reports from 2024 to 2025